文献速递免疫规划传染病防控与疫情报告

BCG疫苗对老年人流感疫苗免疫应答及感染率影响的随机对照试验

Evaluating the non-specific effects of BCG vaccination on the immune system and serological response to influenza vaccination in the elderly: A randomised controlled trial.
PubMed 文献 · Vaccine · 2026-02-05

该随机对照试验纳入273名65岁以上丹麦公民,比较BCG与灭活流感疫苗不同顺序联合接种与单独接种流感疫苗的效果。结果显示,接种流感疫苗后4周各血清型HI抗体平均倍数变化为2.3-2.5,组间无显著差异;6个月随访感染率组间无差异,且与抗体水平无关。BCG未增强流感疫苗血清学应答或降低感染风险。

要点

  • BCG与流感疫苗联合接种未提高老年人流感抗体滴度。
  • BCG未降低6个月随访期间的感染率。
  • 未发现BCG诱导训练免疫的明确证据。

核心结论

  • 在丹麦老年人群中,BCG接种未增加对季节性流感疫苗的血清学应答,也未降低感染发生率。

研究设计与样本

  • 随机对照试验,嵌套免疫学研究,纳入273名65岁以上丹麦公民,随机分为四组,BCG与灭活流感疫苗不同顺序联合接种对比单独接种流感疫苗。

主要发现

  • 流感疫苗接种后4周,所有血清型HI抗体平均倍数变化为2.3-2.5,治疗组间无显著差异。
  • 血清转化率在治疗组间及年龄、性别分层中相当。
  • 组间感染率无差异,且感染率与流感抗体水平无关联。
  • 淋巴细胞分布无差异。
  • 与单独接种流感疫苗相比,BCG联合流感疫苗对体外细胞因子产生有适度影响。

临床怎么用

  • 不建议为增强老年人流感疫苗免疫应答或降低感染风险而常规联合接种BCG。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: The Bacillus Calmette-Guerin (BCG) vaccine has beneficial effects on the immune system, which may lead to non-specific protection against non-tuberculous infections and increase the response to subsequent vaccinations. Seasonal influenza vaccination is used to protect senior citizens against influenza, but the serological response to the inactivated influenza vaccine (IIV) decreases in the elderly due to immunosenescence. The aim of this study was to test the capacity of BCG to boost the specific immune response to IIV and explore the effect of BCG on the innate immune system and health of senior citizens. METHODS: A randomised controlled trial with a nested immunological study including 273 Danish citizens >65 years. Participants were randomised into four equally sized groups combining BCG with IIV in different sequences compared with IIV alone. The primary outcome was change in influenza antibody hemagglutination inhibition (HI) titre four weeks after vaccination. Secondary outcomes were infection rate during six months follow-up, and association between influenza antibody titre and infection rate. In subgroup analyses, we explored the effect of BCG on lymphocyte populations seven days after IIV and on cytokine production after stimulation of mononuclear cells in vitro. RESULTS: Four weeks after influenza vaccination, the mean fold change in HI titre over all serotypes was 2.3-2.5 with no significant differences between the treatment groups. Seroconversion rate was comparable between treatment groups, and in strata of age and sex. There was no difference in the rate of infection between the groups and there was no association with influenza antibody level. We found no difference in distribution of lymphocytes. Combining BCG with IIV had modest impact on in vitro cytokine production compared with IIV alone. CONCLUSION: BCG vaccination did not increase serological response to seasonal influenza vaccination or reduce the incidence of infection in this population of Danish senior citizens. TRIAL REGISTRATION: EU Clinical Trials Register (EudraCT number 2019-002781-12). SUMMARY: In this randomised clinical trial of Danish senior citizens, BCG vaccination did not influence serological response to influenza vaccination or reduce the risk of infection compared with placebo. There was no clear indication of induction of trained immunity.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Madsen AMR, Schaltz-Buchholzer F, Trebbien R, et al. Evaluating the non-specific effects of BCG vaccination on the immune system and serological response to influenza vaccination in the elderly: A randomised controlled trial. Vaccine. 2026. PMID: 41650670. doi:10.1016/j.vaccine.2026.128305

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。